Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development
- CEPI to provide an initial
$4 millionto accelerate vaccine development to prepare for Phase 1
- Multiple vaccine candidates being tested in preclinical studies prior to advancing to human trials
- Phase 1 clinical trial expected to initiate in late spring of 2020
“This first stage of funding from CEPI is critical to enable ongoing development of our COVID-19 vaccine candidates,” said
“The current crisis shows that we cannot prevent all infectious diseases from emerging. But we can and must double down on developing vaccines,” said
A new strain of coronavirus first appeared in late 2019 in
Novavax’ patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.
CEPI is an innovative partnership between public, private, philanthropic, and civil organizations, launched at
Statements herein relating to the future of
Source: Novavax, Inc.